Market Research Logo

Glomerulonephritis - Pipeline Review, H2 2015

Glomerulonephritis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Glomerulonephritis - Pipeline Review, H2 2015’, provides an overview of the Glomerulonephritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glomerulonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glomerulonephritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Glomerulonephritis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Glomerulonephritis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Glomerulonephritis Overview
Therapeutics Development
Pipeline Products for Glomerulonephritis - Overview
Pipeline Products for Glomerulonephritis - Comparative Analysis
Glomerulonephritis - Therapeutics under Development by Companies
Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes
Glomerulonephritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Glomerulonephritis - Products under Development by Companies
Glomerulonephritis - Products under Investigation by Universities/Institutes
Glomerulonephritis - Companies Involved in Therapeutics Development
Adienne Pharma & Biotech
Alexion Pharmaceuticals, Inc.
Anthera Pharmaceuticals‚ Inc.
Avexxin AS
Biogen, Inc.
Cyclacel Pharmaceuticals, Inc.
FibroStatin SL
Fortress Biotech, Inc.
GlaxoSmithKline Plc
Hansa Medical AB
Mallinckrodt Plc
Pfizer Inc.
Pharmalink AB
Rigel Pharmaceuticals, Inc.
Toray Industries, Inc.
Glomerulonephritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Adipose Stem Cell Therapy for IgA Nephropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AVX-235 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
blisibimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DEXM-74 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Inhibit GPBP for Glomerulonephritis and Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endoglycosidase of Streptococcus pyogenes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fostamatinib disodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mubodina - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBF-1472 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-1355 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glomerulonephritis - Recent Pipeline Updates
Glomerulonephritis - Dormant Projects
Glomerulonephritis - Discontinued Products
Glomerulonephritis - Product Development Milestones
Featured News & Press Releases
Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon
Sep 09, 2011: Adienne Pharma Receives EMA's Positive Opinion For Orphan Drug Designation For Recombinant Human Minibody Mubodina
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon
Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Glomerulonephritis, H2 2015
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Glomerulonephritis - Pipeline by Adienne Pharma & Biotech, H2 2015
Glomerulonephritis - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Glomerulonephritis - Pipeline by Anthera Pharmaceuticals‚ Inc., H2 2015
Glomerulonephritis - Pipeline by Avexxin AS, H2 2015
Glomerulonephritis - Pipeline by Biogen, Inc., H2 2015
Glomerulonephritis - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Glomerulonephritis - Pipeline by FibroStatin SL, H2 2015
Glomerulonephritis - Pipeline by Fortress Biotech, Inc., H2 2015
Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H2 2015
Glomerulonephritis - Pipeline by Hansa Medical AB, H2 2015
Glomerulonephritis - Pipeline by Mallinckrodt Plc, H2 2015
Glomerulonephritis - Pipeline by Pfizer Inc., H2 2015
Glomerulonephritis - Pipeline by Pharmalink AB, H2 2015
Glomerulonephritis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2015
Glomerulonephritis - Pipeline by Toray Industries, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Glomerulonephritis Therapeutics - Recent Pipeline Updates, H2 2015
Glomerulonephritis - Dormant Projects, H2 2015
Glomerulonephritis - Dormant Projects (Contd..1), H2 2015
Glomerulonephritis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Glomerulonephritis, H2 2015
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report